FDA 483 - Patheon Biologics LLC - January 24, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Patheon Biologics LLC, a drug substance manufacturer in Saint Louis, MO, revealed significant deficiencies across multiple areas. Observations included inadequate facility cleaning and maintenance leading to mold contamination, insufficient control of manufacturing processes, and incomplete risk assessments for viral contamination. Additionally, issues were noted with the segregation and management of expired raw materials, inadequate maintenance programs, and improper labeling of GMP materials and equipment.
ID · 873b0edd-030b-43fa-98b0-e9085b4a11de